辛伐他汀并氯吡格雷对急性冠脉综合症患者高敏C反应蛋白及血脂的影响  

Effects of simvastatin combined with clopidogrel on hs-CRP and blood lipids in patients with acute coronary syndrome

作　　者：周贻 丁远英 陈少伟 

机构地区：[1]湘潭市中心医院,湖南湘潭市411100

出　　处：《心血管康复医学杂志》2009年第2期152-154,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨辛伐他汀联用氢氯吡格雷对急性冠脉综合症患者高敏C反应蛋白(hs-CRP)及血脂的影响。方法:117例急性冠脉综合征患者被分成辛伐他汀常规治疗组(48例)和辛伐他汀联用氢氯吡格雷组(69例)。观察治疗后6周两组血浆hs-CRP和血脂含量的变化。结果:两组患者治疗后6周血浆hs-CRP、血脂水平均显著下降(P<0.01),但辛伐他汀联用氢氯吡格雷组的hs-CRP下降幅度较辛伐他汀组更大(P<0.05),两组血脂改善无显著差异(P>0.05)。结论:辛伐他汀联用氢氯吡格雷应用于急性冠脉综合征患者,能更有效地降低血浆hs-CRP浓度,更有利于抑制炎症、稳定斑块。Objective： To investigate the effects of simvastatin combined with clopidogrel on high sensitivity C--reactive protein （hs--CRP） and blood lipids in patients with acute coronary syndrome （ACS） . Methods： A total of 117 patients with ACS were divided into two groups： simvastatin group （48 patients） and simvastatin combined with clopidogrel group （69 patients）. The levels of hs--CRP and blood lipids were detected before and six-week after treatment. Results： The hs--CRP and blood lipids levels of patients significantly decreased in two groups （P〈0.01 all）. Compared with simvastatin group, the hs--CRP levels significantly decreased （P〈0. 05）, but the blood lipids levels had not significant decreased （P〉0. 05） in simvastatin combined with clopidogrel group. Conclusion： Treatment with simvastatin combination with clopidogrel not only decrease the blood lipids levels but also has the best effects on lowering hs--CRP. It suggest that it may inhibit inflammatory responses, increase atherosclerotic plaque stabilization in ACS patients.

关 键 词：冠状动脉疾病 辛伐他汀 氢氯吡格雷 C反应蛋白质 

分 类 号：R541.4[医药卫生—心血管疾病]